Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06072482 · ClinicalTrials.gov registry record · Phase 4
A Study to Evaluate Avacopan in Participants With ANCA-associated Vasculitis
A Phase 4 study of Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, sponsored by Amgen.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 300
- Enrollment target
- 20
- Study locations
NCT06072482: Recruiting Phase 4 study of Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, sponsored by Amgen.
NCT06072482 is a Phase 4 study of Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis that is actively recruiting participants, run by Amgen. The registered enrollment target is 300 participants, above the 54-participant average among 5 other Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis trials with a reported enrollment target (456% higher). The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06072482, a Phase 4 study of Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, is actively recruiting participants, sponsored by Amgen.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 300 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objective of this study is to evaluate the long-term safety of avacopan in participants with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Standard of Care
- DRUG Avacopan
Study Locations (20)
California
- Medvin Clinical Research - Covina
- Palo Alto Medical Foundation Fremont - Fremont
- The Nephrology Group - Fresno
- Providence Medical Foundation - Fullerton
- Medvin Clinical Research - Menifee
- University of California San Francisco- Zuckerburg San Francisco General - San Francisco
- Harbor University of California at Los Angeles Medical Center - Torrance
Florida
- Florida Kidney Physicians - Boca Raton
- Malcom Randall Veterans Affairs Medical Center - Gainesville
- Mayo Clinic - Jacksonville
- ClinTrial Research Oakwater, Llc - Orlando
- University of South Florida - Tampa
Arizona
- Scottsdale Healthcare at Shea - HonorHealth - Scottsdale
- Southwest Kidney Institute - Surprise
Iowa
- University of Iowa Hospitals and Clinics - Iowa City
- Dunes Clinical Research LLC - Sioux City
Alaska
- Orthopedic Physicians Alaska - Anchorage
Colorado
- University of Colorado - Aurora
Georgia
- Emory University - Atlanta
Indiana
- Lake Cumberland Rheumatology - New Albany
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2024-02-07 |
| Est. Completion | 2036-12-31 |
| Phase | Phase 4 |
What NCT06072482 shows while recruiting
NCT06072482 is an interventional study that assigns participants to a tested intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap, above the 54-participant average among 5 other Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis trials with a reported enrollment target (456% higher).
The record links to 1 condition, with Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT06072482 names 20 study sites across 8 states, led by California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT06072482 about?
NCT06072482 is a clinical study titled "A Study to Evaluate Avacopan in Participants With ANCA-associated Vasculitis". The primary objective of this study is to evaluate the long-term safety of avacopan in participants with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV).
What is the current status of trial NCT06072482?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 300 participants. The study started on 2024-02-07. Estimated completion is 2036-12-31.
What conditions does trial NCT06072482 study?
This clinical trial studies the following conditions: Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis.
What interventions are being tested in trial NCT06072482?
The interventions under investigation include: Placebo (DRUG), Standard of Care (DRUG), Avacopan (DRUG).
Who is sponsoring clinical trial NCT06072482?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06072482 being conducted?
This trial has 20 study locations across Alaska, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)
RECRUITING · Phase 1
-
Study Evaluating SC291 in Subjects With Severe r/r B-cell Mediated Autoimmune Diseases (GLEAM)
ACTIVE NOT RECRUITING · Phase 1
-
An Open-label Study of Povetacicept in Autoantibody-Associated Glomerular Diseases
ACTIVE NOT RECRUITING · Phase 1
-
A Study in Healthy Volunteers to Evaluate the Pharmacokinetic Food Effect and Cardiac Safety of CCX168
COMPLETED · Phase 1
-
A Study in Healthy Volunteers to Evaluate the Drug-Drug Interaction Potential of CCX168 With Concomitant Medications
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00353483 · 300 participants
Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells
- NCT00588185 · 300 participants · NA
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer
- NCT00682032 · 300 participants · NA
The Effect of Beta-glucan in Non-Small Cell Lung Cancer
- NCT00870064 · 300 participants · NA
The Treatment of Type I Open Fractures in Pediatrics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI